乙型肝炎病毒核心相关抗原和乙型肝炎表面抗原对聚乙二醇

StephenW

Infect Dis (Lond). 2018 Feb 20:1-9. doi: 10.1080/23744235.2018.1442018. [Epub ahead of print]
Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy.Wang ML1, Liao J1, Wei B2, Zhang DM1, He M1, Tao MC2, Chen EQ1, Tang H1.
Author information
1a Center of Infectious Diseases, West China Hospital, Sichuan University , Chengdu , People's Republic of China.2b Department of Laboratory Medicine , West China Hospital, Sichuan University , Chengdu , PR China.

AbstractAIM: Recent studies revealed that both quantitative hepatitis B surface antigen (qHBsAg) and hepatitis B core-related antigen (qHBcrAg) could serve as a good marker for predicting treatment response and indirectly reflecting intrahepatic cccDNA levels. This study aimed to compare the value of qHBsAg and qHBcrAg in predicting HBeAg seroconversion among patients undergoing PEG-IFN therapy.
METHODS: A total of 31 HBeAg-positive patients, who underwent PEG-IFN therapy for 12 months and follow-up for six months were retrospectively included in this study. The serum qHBsAg level was measured using Elecsys® HBsAg II Quant Assay and serum qHBcrAg level was measured using chemiluminescence enzyme immunoassay.
RESULTS: During the 12-month treatment, the absolute levels of serum qHBsAg and qHBcrAg were both lower in patients with HBeAg seroconversion as compared to patients without HBeAg seroconversion, but only the difference in qHBcrAg was significant. During the 6-month follow-up period, both qHBsAg and qHBcrAg levels were rebounded significantly among patients without HBeAg seroconversion. Among patients with HBeAg seroconversion, no sustained significant decline of qHBsAg was observed, but serum qHBcrAg levels continued to decline significantly. The ROC curves analysis showed that both absolute qHBcrAg level and the extent of qHBcrAg decline at month 1 had better performance for the prediction of HBeAg seroconversion at month 6 after treatment, as compared to that of qHBsAg.
CONCLUSION: Early on-treatment qHBcrAg may be a good biomarker for predicting off-treatment HBeAg seroconversion in patients receiving PEG-IFN therapy.


KEYWORDS: Chronic hepatitis B; Hepatitis B core-related antigen; Hepatitis B e antigen seroconversion; Hepatitis B surface antigen; Pegylated interferon therapy

PMID:29463147DOI:10.1080/23744235.2018.1442018

StephenW

感染Dis（隆德）。 2018年2月20日：1-9。 doi：10.1080 / 23744235.2018.1442018。 [电子版提前打印]
乙型肝炎病毒核心相关抗原和乙型肝炎表面抗原对聚乙二醇干扰素治疗慢性乙型肝炎患者HBeAg血清学转换的比较。
王ML1，廖继1，魏B2，张DM1，何M1，陶MC2，陈EQ1，唐H1。
作者信息

1
    四川大学华西医院传染病中心，成都，中华人民共和国。
2
    b四川大学华西医院检验科，成都，中国。

抽象
目标：

最近的研究表明，定量乙型肝炎表面抗原（qHBsAg）和乙型肝炎核心相关抗原（qHBcrAg）可以作为预测治疗反应和间接反映肝内cccDNA水平的良好标志物。本研究旨在比较qHBsAg和qHBcrAg在预测接受PEG-IFN治疗的患者中HBeAg血清学转换的价值。
方法：

本研究回顾性总结了31例接受PEG-IFN治疗12个月和随访6个月的HBeAg阳性患者。使用Elecsys®HBsAg II Quant Assay测量血清qHBsAg水平，并使用化学发光酶免疫测定法测量血清qHBcrAg水平。
结果：

在治疗12个月期间，HBeAg血清学转换患者的血清qHBsAg和qHBcrAg的绝对水平均低于无HBeAg血清学转换的患者，但只有qHBcrAg的差异显着。在6个月的随访期间，无HBeAg血清学转换的患者qHBsAg和qHBcrAg水平均显着反弹。在HBeAg血清学转换的患者中，未观察到qHBsAg持续显着下降，但血清qHBcrAg水平继续显着下降。 ROC曲线分析显示，与qHBsAg相比，治疗后6个月，绝对qHBcrAg水平和1个月qHBcrAg下降程度在预测HBeAg血清转换方面有更好的表现。
结论：

早期治疗中qHBcrAg可能是预测接受PEG-IFN治疗的患者治疗后HBeAg血清转换的良好生物标志物。
关键词：

慢性乙型肝炎;乙型肝炎核心相关抗原;乙型肝炎e抗原血清转换;乙型肝炎表面抗原;聚乙二醇干扰素治疗

结论：
    29463147
DOI：
    10.1080 / 23744235.2018.1442018

rxsm

我学浅，看你帖好比读文言文。
感谢你所做的一切，新年好！

jdcy

rxsm 发表于 2018-2-23 23:00
我学浅，看你帖好比读文言文。
感谢你所做的一切，新年好！

赞同！提炼一下就好了！新年好！

antiHBVren

HBcrAg的临床意义，有待谨慎乐观地对待；
对于长期抗病毒的战友，没有什么卵用